Antidepressant-like effects of rosiglitazone, a PPARγ agonist, in the rat forced swim and mouse tail suspension tests
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Several studies have evaluated thiazolidinedione therapy as medical treatments for some central nervous system disorders, such as cognitive deficits associated with neurodegenerative disorders. However, there is limited data to support a direct role for peroxisome proliferator-activated receptor-γ agonists in depression. Therefore, the aim of this study was to investigate antidepressant-like activity of rosiglitazone using the mouse tail suspension test and the rat forced swimming test, two models sensitive to the effects of antidepressants. In the tail suspension test, 5 days of treatment with rosiglitazone (8.5 or 17 mg/kg, orally) reduced immobility time. In the forced swimming test, rosiglitazone (6 or 12 mg/kg, orally) treatment decreased immobility time and increased climbing. These effects were not accompanied by any alteration in locomotor activity in the open field test. Rosiglitazone treatment (6 or 12 mg/kg, orally) significantly reduced plasma corticosterone levels in rats. GW9662 significantly inhibited the rosiglitazone-induced reduction in the duration of immobility. In summary, this study suggests that rosiglitazone possesses a specific antidepressant-like activity in behavioral models and that this effect may be mediated by reduction of plasma corticosterone level.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Depression: a new animal model sensitive to antidepressant treatments
PORSOLT, R. D., LE PICHON, M., & JALFRE, M. (1977) · Nature · doi:10.1038/266730a0 · Cited by 4,451 · cited 1×
“The tail suspension test (TST) and forced swimming test (FST) are two behavioral models that have gained broad acceptance for the assessment of pharmacological antidepressant activity (Porsolt et al., 1977; Bourin et al., 2001).”
BackgroundThe tail suspension test: A new method for screening antidepressants in mice
Steru, L., Chermat, R., Thierry, B., & Simon, P. (1985) · Psychopharmacology · doi:10.1007/bf00428203 · Cited by 3,534 · cited 1×
“Immobility was induced by tail suspension according to the procedure of Steru et al. (1985).”
MethodBehavioural despair in rats: A new model sensitive to antidepressant treatments
Porsolt, R. D., Anton, G., Blavet, N., & Jalfre, M. (1978) · European Journal of Pharmacology · doi:10.1016/0014-2999(78)90118-8 · Cited by 3,138
Neurocircuitry of stress: central control of the hypothalamo–pituitary–adrenocortical axis
Herman, J. P., & Cullinan, W. E. (1997) · Trends in Neurosciences · doi:10.1016/s0166-2236(96)10069-2 · Cited by 2,270 · cited 1×
“Corticotropinreleasing factor (CRF) is the major peptide released upon activation of the HPA axis in response to stress, resulting in the release of adrenal glucocorticoids (cortisol in humans and corticosterone in rodents) into the circulatory system (Herman and Cullinan, 1977).”
Assessing antidepressant activity in rodents: recent developments and future needs
Cryan, J. F., Markou, A., & Lucki, I. (2002) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(02)02017-5 · Cited by 1,551 · cited 2×
“These findings are in agreement with previous reports indicating that antidepressant drugs that inhibit norepinephrine reuptake (desipramine or reboxetine) effectively reduced immobility and selectively increased climbing behavior without affecting swimming, whereas the selective serotonin reuptake inhibitor (fluoxeti…”
BackgroundResultSorting out the roles of PPAR in energy metabolism and vascular homeostasis
Lefebvre, P. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27989 · Cited by 962
Association of depression with medical illness: Does cortisol play a role?
Brown, E. S., Varghese, F. P., & McEwen, B. S. (2004) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00473-6 · Cited by 578 · cited 2×
“, 2002), as they are usually associated with significant functional impairment and health care cost (Brown et al., 2004).”
BackgroundMizoguchi, K., Yuzurihara, M., Ishige, A., Sasaki, H., Chui, D.-H., & Tabira, T. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-04-01568.2000 · Cited by 481 · cited 2×
“Similarly, glucocorticoids are necessary for normal cognitive function mediated by cortical areas (Mizoguchi et al., 2004), yet chronic stress in rats causes memory deficits that result from reduced glucocorticoid responses in the prefrontal cortex (Mizoguchi et al., 2000).”
BackgroundMetyrapone as Additive Treatment in Major Depression: A Double-blind and Placebo-Controlled Trial
Jahn, H., Schick, M., Kiefer, F., Kellner, M., Yassouridis, A., & Wiedemann, K. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.12.1235 · Cited by 184 · cited 1×
“A recent study found that the addition of metyrapone to a standard serotonergic antidepressant was more effective than the addition of a placebo in augmenting the antidepressant response (Jahn et al., 2004).”
BackgroundApoE deficiency leads to a progressive age-dependent blood-brain barrier leakage
Hafezi-Moghadam, A., Thomas, K. L., & Wagner, D. D. (2007) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00563.2005 · Cited by 149 · cited 2×
“…for the ability of rosiglitazone to cross the blood–brain barrier has been limited, but recent data from a number of groups have indicated that rosiglitazone can pass through the blood–brain barrier (Bake and Sohrabji, 2004; Hafezi-Moghadam et al., 2007; Loane et al., 2007; Strum et al., 2007).”
Background
Cited by
Singh, M. (2014) · Frontiers in Psychology · doi:10.3389/fpsyg.2014.00925 · Cited by 337
Yau, S. Y., Li, A., Hoo, R. L. C., Ching, Y. P., Christie, B. R., Lee, T. M. C., Xu, A., & So, K.-F. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1415219111 · Cited by 326
“PPARy agonist has also been shown to exert a potent antidepressant effect (48, 49).”
BackgroundMetabolic disturbances connecting obesity and depression
Hryhorczuk, C., Sharma, S., & Fulton, S. E. (2013) · Frontiers in Neuroscience · doi:10.3389/fnins.2013.00177 · Cited by 322
Sepanjnia, K., Modabbernia, A., Ashrafi, M., Modabbernia, M.-J., & Akhondzadeh, S. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.58 · Cited by 153
Kashani, L., Omidvar, T., Farazmand, B., Modabbernia, A., Ramzanzadeh, F., Tehraninejad, E. S., Ashrafi, M., Tabrizi, M., & Akhondzadeh, S. (2013) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2012.08.010 · Cited by 116
Metadata
- Authors
- Eissa Ahmed, A. A., Al-Rasheed, N. M., & Al-Rasheed, N. M.
- Venue
- Behavioural Pharmacology
- Published
- 2009-10
- Volume
- 20
- Issue
- 7
- Pages
- 635-642
- ISSN
- 0955-8810 (ISSN-L)
- OpenAlex
- W2082823754
- Cited by
- 81
- References
- 11
- FWCI
- 3.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antidepressant-like effects of rosiglitazone, a PPARγ agonist, in the rat forced swim and mouse tail suspension tests. https://app.cochat.ai/papers/10.1097/fbp.0b013e328331b9bf
- The paper
- Eissa Ahmed, A. A., Al-Rasheed, N. M., & Al-Rasheed, N. M. (2009). Antidepressant-like effects of rosiglitazone, a PPARγ agonist, in the rat forced swim and mouse tail suspension tests. Behavioural Pharmacology. https://doi.org/10.1097/fbp.0b013e328331b9bf
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.